2021 Year in Review - Multiple Myeloma
2021 Year in Review - Multiple Myeloma | February 23, 2022
Updated analysis of the first-in-human phase 1/2 trial showed that BCMA x CD3 bispecific monoclonal antibody REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talquetamab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination.
2021 Year in Review - Multiple Myeloma | February 23, 2022
A subgroup analysis of the FORTE study found that carfilzomib-lenalidomide-dexamethasone induction/consolidation (KRd) plus ASCT and carfilzomib-lenalidomide maintenance provided survival benefit to patients of all cytogenetic risk groups, including patients at high risk.
2021 Year in Review - Multiple Myeloma | February 23, 2022
A simulation modeling that incorporated clinically representative sequences for patients with transplant-ineligible NDMM and included attrition rates supports using the D-Rd regimen in the first-line setting instead of reserving it for later lines of therapy.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Final analysis results of the LYRA study demonstrated that daratumumab in combination with CyBorD induction therapy and as maintenance yielded durable and deep responses in patients with newly diagnosed or recurrent MM irrespective of ASCT status, with no new safety signals.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Preliminary results of the phase 1 MagnetisMM-1 study indicated that the BCMA-targeted CD3-engaging bispecific molecule elranatamab had a manageable safety profile and induced deep and durable clinical responses as a single agent in heavily treated patients with RRMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Results of part B of a phase 1b trial showed that the addition of isatuximab (using the short-duration, fixed-volume infusion method) to standard-of-care VRd was feasible, safe, and effective in patients with NDMM ineligible or with no immediate intent for ASCT.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Results of a phase 2 IFM study demonstrated that quadruplet combination regimen of D-IRD as induction and consolidation therapy after ASCT followed by lenalidomide maintenance therapy was safe and resulted in increased depth of responses over time in standard-risk patients with NDMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Results of the phase 2 HOVON 143 study indicate that ixazomib, daratumumab, and dexamethasone is an effective and feasible regimen in intermediate-fit patients with non–transplant-eligible NDMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Corneal event management guidelines were developed with the goal of assisting practicing hematologists/oncologists in assessing and managing belantamab mafodotin–associated ocular events so that patients may continue to maximize clinical benefit with belantamab mafodotin therapy.